Product Information
VESICARE LS 5 MG/5 ML SUSP is a brand product labeled by Astellas Pharma US, Inc., priced at $1.6383 per ML under NDC 51248025099. Its NADAC has been published 120 times since Apr 17, 2024.
FDA first approved this application on May 26, 2020.
The High Outlier badge above means this manufacturer's average price in the solifenacin succinate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/mL
Manufacturer
Astellas Pharma US, Inc.NDC
51248025099
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
SOLIFENACIN SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA209529FDA Approved
5/26/2020
On Market Since
5/26/2020
Pharmacological Classes
Price Statistics
The NADAC for VESICARE LS 5 MG/5 ML SUSP has been published 120 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.6383 per ML |
|---|---|
| All-time high | $1.6421 (Sep 11, 2024) |
| All-time low | $1.6360 (May 21, 2025) |
| 52-week high | $1.6383 |
| 52-week low | $1.6383 |
| Median price | $1.6383 |
| Average price | $1.6387 |
| Largest weekly change | -0.3% (Dec 18, 2024) |
| Weeks tracked | 120 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
0.0%
3M
0.0%
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
-0.1%
Last surveyed Jul 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the solifenacin succinate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VESICARE LS 5 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for VESICARE LS 5 MG/5 ML SUSP, manufactured by Astellas Pharma US, Inc., is $1.6383 per ML (NDC 51248025099), effective Jul 29, 2026.
How has the price of VESICARE LS 5 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for VESICARE LS 5 MG/5 ML SUSP has held within roughly two percent of its current level. It has been tracked across 120 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for VESICARE LS 5 MG/5 ML SUSP?
Since Apr 17, 2024, the NADAC for VESICARE LS 5 MG/5 ML SUSP has ranged from a low of $1.6360 (May 21, 2025) to a high of $1.6421 (Sep 11, 2024), with a median of $1.6383 per ML.
Are there cheaper alternatives to VESICARE LS 5 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of VESICARE LS 5 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VESICARE LS 5 MG/5 ML SUSP?
VESICARE LS 5 MG/5 ML SUSP (NDC 51248025099) is labeled by Astellas Pharma US, Inc., and CMS classifies it as a brand product.